-
Je něco špatně v tomto záznamu ?
Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe
F. Rencz, L. Gulácsi, M. Péntek, KB. Gecse, A. Dignass, J. Halfvarson, F. Gomollón, P. Baji, L. Peyrin-Biroulet, PL. Lakatos, V. Brodszky,
Jazyk angličtina Země Velká Británie
Typ dokumentu srovnávací studie, časopisecké články
Odkazy
PubMed
28434387
DOI
10.1080/14737167.2017.1322509
Knihovny.cz E-zdroje
- MeSH
- adalimumab aplikace a dávkování ekonomika terapeutické užití MeSH
- analýza nákladů a výnosů MeSH
- biosimilární léčivé přípravky aplikace a dávkování ekonomika terapeutické užití MeSH
- Crohnova nemoc farmakoterapie ekonomika MeSH
- ekonomické modely MeSH
- gastrointestinální látky aplikace a dávkování ekonomika terapeutické užití MeSH
- humanizované monoklonální protilátky aplikace a dávkování ekonomika terapeutické užití MeSH
- infliximab aplikace a dávkování ekonomika terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- kvalitativně upravené roky života MeSH
- lidé MeSH
- Markovovy řetězce MeSH
- randomizované kontrolované studie jako téma MeSH
- rozvrh dávkování léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries. METHODS: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials. Country-specific unit costs, discount rates and a third-party payer perspective were applied. RESULTS: The bsIFX versus conventional therapy resulted in the most favourable incremental cost-utility ratios (ICURs) ranging from €34,580 (Hungary) to €77,062/QALY (Sweden). Compared to bsIFX, the bsIFX-ADA sequence was more cost-effective than the bsIFX-VEDO sequence with ICURs varying between €70,277 (France) and €162,069/QALY (Germany). The ICURs of the bsIFX-ADA-VEDO sequence versus the bsIFX-ADA strategy were between €206,266 (The Netherlands) and €363,232/QALY (Spain). CONCLUSION: We are the first to compare cost-effectiveness of multiple biological sequences for luminal Crohn's disease. Based on our findings, bsIFX can be recommended as a first-line treatment in patients unresponsive to conventional treatments. While biological sequences only slightly differ in their associated health gains, their costs vary greatly. The bsIFX-ADA-VEDO seems to be the most cost-effective sequence of the available biologics across Europe.
b 1st Department of Medicine Semmelweis University Budapest Hungary
c Department of Medicine 1 Agaplesion Markus Krankenhaus Frankfurt Germany
Department of Gastroenterology Faculty of Medicine and Health Örebro University Örebro Sweden
Department of Health Economics Corvinus University of Budapest Budapest Hungary
e Gastroenterology Unit Clinical Universitary Hospital Lozano IIS Aragón Zaragoza Spain
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016648
- 003
- CZ-PrNML
- 005
- 20180521094938.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14737167.2017.1322509 $2 doi
- 035 __
- $a (PubMed)28434387
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Rencz, Fanni $u a Department of Health Economics , Corvinus University of Budapest , Budapest , Hungary.
- 245 10
- $a Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe / $c F. Rencz, L. Gulácsi, M. Péntek, KB. Gecse, A. Dignass, J. Halfvarson, F. Gomollón, P. Baji, L. Peyrin-Biroulet, PL. Lakatos, V. Brodszky,
- 520 9_
- $a BACKGROUND: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries. METHODS: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials. Country-specific unit costs, discount rates and a third-party payer perspective were applied. RESULTS: The bsIFX versus conventional therapy resulted in the most favourable incremental cost-utility ratios (ICURs) ranging from €34,580 (Hungary) to €77,062/QALY (Sweden). Compared to bsIFX, the bsIFX-ADA sequence was more cost-effective than the bsIFX-VEDO sequence with ICURs varying between €70,277 (France) and €162,069/QALY (Germany). The ICURs of the bsIFX-ADA-VEDO sequence versus the bsIFX-ADA strategy were between €206,266 (The Netherlands) and €363,232/QALY (Spain). CONCLUSION: We are the first to compare cost-effectiveness of multiple biological sequences for luminal Crohn's disease. Based on our findings, bsIFX can be recommended as a first-line treatment in patients unresponsive to conventional treatments. While biological sequences only slightly differ in their associated health gains, their costs vary greatly. The bsIFX-ADA-VEDO seems to be the most cost-effective sequence of the available biologics across Europe.
- 650 _2
- $a adalimumab $x aplikace a dávkování $x ekonomika $x terapeutické užití $7 D000068879
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $x ekonomika $x terapeutické užití $7 D061067
- 650 _2
- $a biosimilární léčivé přípravky $x aplikace a dávkování $x ekonomika $x terapeutické užití $7 D059451
- 650 _2
- $a analýza nákladů a výnosů $7 D003362
- 650 _2
- $a Crohnova nemoc $x farmakoterapie $x ekonomika $7 D003424
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a Evropa $7 D005060
- 650 _2
- $a gastrointestinální látky $x aplikace a dávkování $x ekonomika $x terapeutické užití $7 D005765
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a infliximab $x aplikace a dávkování $x ekonomika $x terapeutické užití $7 D000069285
- 650 _2
- $a Markovovy řetězce $7 D008390
- 650 _2
- $a ekonomické modely $7 D018803
- 650 _2
- $a kvalitativně upravené roky života $7 D019057
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gulácsi, László $u a Department of Health Economics , Corvinus University of Budapest , Budapest , Hungary.
- 700 1_
- $a Péntek, Márta $u a Department of Health Economics , Corvinus University of Budapest , Budapest , Hungary.
- 700 1_
- $a Gecse, Krisztina B $u b 1st Department of Medicine , Semmelweis University , Budapest , Hungary.
- 700 1_
- $a Dignass, Axel $u c Department of Medicine 1 , Agaplesion Markus Krankenhaus , Frankfurt , Germany.
- 700 1_
- $a Halfvarson, Jonas $u d Department of Gastroenterology, Faculty of Medicine and Health , Örebro University , Örebro , Sweden.
- 700 1_
- $a Gomollón, Fernando $u e Gastroenterology Unit , Clinical Universitary Hospital Lozano IIS Aragón (Blesa, IIS Aragón, CIBEREHD) , Zaragoza , Spain.
- 700 1_
- $a Baji, Petra $u a Department of Health Economics , Corvinus University of Budapest , Budapest , Hungary. f Center for Economic Research and Graduate Education (CERGE) Economics Institute (EI) Research Fellow , Charles University , Praha 1 , The Czech Republic.
- 700 1_
- $a Peyrin-Biroulet, Laurent $u g Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois , Lorraine University , Vandoeuvre-lès-Nancy , France.
- 700 1_
- $a Lakatos, Peter L $u b 1st Department of Medicine , Semmelweis University , Budapest , Hungary.
- 700 1_
- $a Brodszky, Valentin $u a Department of Health Economics , Corvinus University of Budapest , Budapest , Hungary.
- 773 0_
- $w MED00174435 $t Expert review of pharmacoeconomics & outcomes research $x 1744-8379 $g Roč. 17, č. 6 (2017), s. 597-606
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28434387 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521095120 $b ABA008
- 999 __
- $a ok $b bmc $g 1300272 $s 1013488
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 17 $c 6 $d 597-606 $e 20170428 $i 1744-8379 $m Expert review of pharmacoeconomics & outcomes research $n Expert rev. pharmacoecon. outcomes res. $x MED00174435
- LZP __
- $a Pubmed-20180515